| Literature DB >> 35450892 |
Pramil N Singh1,2, Olivia Moses2,3, Wendy Shih2, Mark Hubbard3.
Abstract
PURPOSE: The purpose of the Loma Linda University Health (LLUH) BREATHE cohort is to test the efficacy of a novel method of continuously incentivising participation in workplace smoking cessation on participation, long-term abstinence, health outcomes, healthcare costs and healthcare utilisation. PARTICIPANTS: In 2014, LLUH-a US academic medical centre and university-incentivised participation in a workplace smoking cessation programme (LLUH BREATHE) by lowering health plan costs. Specifically, LLUH introduced a Wholeness Health Plan (WHP) option that, for the smokers, continuously incentivises participation in nicotine screening and the LLUH BREATHE smoking cessation programme by offering an 'opt-in wellness discount' that consisted of 50%-53% lower out of pocket health plan costs (ie, monthly employee premiums, copayments). This novel 'continuously incentivised' model lowers annual health plan costs for smokers who, on an annual basis, attempt or maintain cessation from tobacco use. The annual WHP cost savings for smokers far exceed the value of short-term incentives that have been tested in workplace cessation trials to date. This ongoing health plan option offered to over 16 000 employees has created an open, dynamic LLUH BREATHE cohort of current and former smokers (n=1092). FINDINGS TO DATE: Our profile of the LLUH BREATHE cohort indicates that after 5 years of follow-up in a prospective cohort study (2014-2019), continuously incentivised smoking cessation produced a 74% participation (95% CI (71% to 77%)) in employer-sponsored smoking cessation attempts that were occurring less than a year after the incentive was offered. The cohort can be purposed to examine the effect of continuously incentivised cessation on cessation outcomes, health plan utilisation/costs, use of electronic nicotine delivery systems, and COVID-19 outcomes. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: COVID-19; EPIDEMIOLOGY; PUBLIC HEALTH
Mesh:
Year: 2022 PMID: 35450892 PMCID: PMC9024252 DOI: 10.1136/bmjopen-2021-053303
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1Enrolment of LLUH BREATHE employee smoker cohort (2014–2019). ENDS, electronic nicotine delivery systems; LLUH, Loma Linda University Health.
Demographics and health among LLUH employees who tested positive for nicotine and were offered participation in an incentivised health plan model for smoking cessation
| Variable | Did not participate (n=282) | Participated (n=810) |
| Age | 42.74 (11.09) | 45.56 (11.49) |
| Gender: n (%) | ||
| Male | 180 (63.83%) | 494 (60.99%) |
| Female | 102 (36.17%) | 316 (39.01%) |
| Enrolment type: n (%) | ||
| Subscriber | 153 (54.26%) | 453 (55.93%) |
| Spouse | 129 (45.74%) | 357 (44.07%) |
| Biometrics | ||
| Weight (lbs) | 191.24 (51.86) | 192.83 (48.06) |
| Body fat (%) | 26.61 (8.9) | 28.05 (9.19) |
| Waist circumference (inches) | 38.46 (6.7) | 39.38 (12.72) |
| BMI (kg/m2) | 29.62 (6.51) | 29.96 (6.41) |
| Systolic blood pressure (mm Hg) | 128.57 (17.02) | 128.3 (17.62) |
| Diastolic blood pressure (mm Hg) | 79.7 (11.76) | 78.62 (11.34) |
| Total cholesterol (mg/dL) | 185.49 (37.95) | 179.77 (35.37) |
| HDL (mg/dL) | 46.75 (16.45) | 44.35 (15.18) |
| HDL ratio | 4.51 (2.1) | 4.5 (1.82) |
| Fasting glucose (mg/dL) | 94.78 (25.97) | 95.39 (29.1) |
| Non-fasting glucose (mg/dL) | 102.08 (21.47) | 103.95 (35.31) |
| LDL (mg/dL) | 115.11 (35.72) | 109.19 (33.39) |
| Triglycerides (mg/dL) | 146.41 (115.38) | 157.81 (117.73) |
LDL = Low-density Lipoprotein; HDL = High-density Lipoprotein
LLUH, Loma Linda University Health.
Figure 2Rate of tobacco screening, incentivised health plan invites, and smoking cessation attempts among LLUH employees (2014–2019). LLUH, Loma Linda University Health.
Figure 3A three-stage Markov model of the smoking cessation relapse process with Latin symbols indicating the transition probabilities. Cessation moves the participants through stages left to right with lapses from long-term abstinence to early abstinence with probability, γ, and lapses from early abstinence to current nicotine users with probability, δ.
Figure 4Transition probability matrix of current stages of nicotine cessation. Current nicotine users who continue to use can remain in the ‘Current Nicotine Users’ stage with a probability of 1−λ or go into the next stage, ‘Early Abstinence’, with probability of λ. Participants in the ‘Early Abstinence’ stage may relapse with a probability of δ, stay in the current ‘Early Abstinence’ stage with a probability of 1-δ-θ, or move to the next phase.